Hong Kong has seen three cases of vaccination deaths in just nine days, and the vaccination rate among Hong Kong people has dropped to 72% due to questions about the safety of the vaccine.
On February 28, the first vaccination death case in Hong Kong occurred in a 63-year-old man who received the vaccine on February 26. On March 3, a 71-year-old man who had been vaccinated by a private clinic was seriously ill on the evening of March 7 and died after resuscitation.
On March 9, the Secretary for the Civil Service, Mr. Nip Tak-kuen, who is responsible for coordinating the vaccination program in Hong Kong, said on a commercial radio program that the recent vaccination rate has reflected public concern. He said the initial vaccination rate of the vaccination program was over 90 percent, but it dropped to 72 percent on March 8, meaning that people who had appointments did not go for the vaccination.
The Hong Kong government announced late on March 8, March 7, a total of eight cases in the community vaccination centers after the injection sent to the hospital, five cases do not need to stay in the hospital, two cases have been discharged, one case in the hospital for observation.
The three cases that were hospitalized were all vaccinated with the Kexin vaccine. A 76-year-old man felt dizziness and numbness on the left side of his body after receiving the vaccination; a 66-year-old woman felt chest pain and palpitations after receiving the vaccination; and a 70-year-old man felt chest discomfort.
There were also three cases of discomfort after receiving the vaccine, including a 61-year-old woman who felt dizzy after receiving the vaccine, another 57-year-old woman who felt headache and palpitations, and another 45-year-old woman who felt headache, rash and itchy neck after receiving the vaccine.
Since Hong Kong began its vaccination program on Feb. 26, more than 93,000 people have received their first dose of the vaccine as of the evening of March 7, including 91,800 people who received the China Kexin vaccine.
The New York Times reported in January that Kexing has now sold more than 300 million doses of the vaccine, mainly to low- and middle-income countries, accounting for about half of the vaccine maker’s total capacity by 2020, as released by China. Hong Kong ordered the first 1 million doses of the Kexing vaccine last month.
It was noted that the data from the third phase of the Kexing vaccine was not published in international medical journals, which is not in line with the standard of admission set by the Hong Kong government earlier, but was still recommended by the expert committee, raising questions.
Recent Comments